US Stock MarketDetailed Quotes
MTNB Matinas BioPharma
- 0.1877
- -0.0023-1.21%
Close Apr 19 16:00 ET
- 0.2000
- +0.0123+6.55%
Post 19:28 ET
47.08MMarket Cap-1706P/E (TTM)
0.1950High0.1824Low388.85KVolume0.1950Open0.1900Pre Close73.88KTurnover0.16%Turnover RatioLossP/E (Static)250.82MShares0.890052wk High2.44P/B45.88MFloat Cap0.110352wk Low--Dividend TTM244.44MShs Float3.9500Historical High--Div YieldTTM6.63%Amplitude0.1103Historical Low0.1890Avg Price1Lot Size
Matinas BioPharma Stock Forum
Sign in to post a comment
Just a bit of info!
$Matinas BioPharma(MTNB.US$ Key Program Updates MAT2203 (Oral Amphotericin B) Program Phase 3 ORALTO Registration Trial ● Matinas reached alignment with the FDA on the design of a single Phase 3 registration trial of oral MAT2203 in patients with invasive aspergillosis who have limited treatment options. This is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients, including those with hematological malignancies...
4
Update
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
1
5
$Matinas BioPharma(MTNB.US$ My final scale is .4013!
News
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203
Update
$Matinas BioPharma(MTNB.US$ Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
5 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
5 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Reminder of possible upcoming catalyst for PI!
$Matinas BioPharma(MTNB.US$ a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces receipt of written feedback from U.S. Food and Drug Administration (FDA) on its proposed revised protocol for a Phase 3 study of MAT2203 in patients with invasive aspergillosis with limited or no treatment options. The preliminary written comments move the Company close...
2
$Matinas BioPharma(MTNB.US$ good news let's buy it
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar8 : We need this medication. Alert to shorters!
TrytosaveabitOP Jaguar8: Yes sir 100% correct! But you really think that most SS’s give two s*its! As long as they make a few bucks who cares if they have to bankrupt a company doing great things for so many in need! Sad but true my friend
Jaguar8 TrytosaveabitOP: I know and they will suffer the wrath of karma
TrytosaveabitOP Jaguar8: Yup